| Literature DB >> 21543939 |
Michael Friedlander1, Edward Trimble, Anna Tinker, David Alberts, Elisabeth Avall-Lundqvist, Mark Brady, Philipp Harter, Sandro Pignata, Eric Pujade-Lauraine, Jalid Sehouli, Ignace Vergote, Philip Beale, Rudd Bekkers, Paula Calvert, Lawrence Copeland, Ros Glasspool, Antonio Gonzalez-Martin, Dionysis Katsaros, Jae Won Kim, Brigitte Miller, Diane Provencher, Lawrence Rubinstein, Mostafa Atri, Alain Zeimet, Monica Bacon, Henry Kitchener, Gavin C E Stuart.
Abstract
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?Entities:
Mesh：
Year: 2011 PMID： 21543939 DOI： 10.1097/IGC.0b013e31821bb8aa
Source DB: PubMed Journal: Int J Gynecol Cancer ISSN： 1048-891X Impact factor: 3.437